Advancements in the front-line treatment of metastatic urothelial carcinoma

Sarah M H Einerhand; Michiel S van der Heijden

doi:10.1016/j.euf.2024.06.003

Advancements in the front-line treatment of metastatic urothelial carcinoma

Eur Urol Focus. 2024 Aug 29:S2405-4569(24)00091-9. doi: 10.1016/j.euf.2024.06.003. Online ahead of print.

Authors

Sarah M H Einerhand¹, Michiel S van der Heijden²

Affiliations

¹ Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

PMID: 39214847
DOI: 10.1016/j.euf.2024.06.003

Abstract

Both the CheckMate-901 (gemcitabine-cisplatin plus nivolumab) trial and the EV-302 (enfortumab-vedotin plus pembrolizumab; EV+P) trial have shown a significant improvement in OS over standard (cis)platinum-based chemotherapy. The effect size, as well as the broader eligibility criteria for EV+P position this regimen as a compelling preferred candidate for the new standard of care in front-line mUC treatment.

Publication types

Practice Guideline